FlashForward™ Consortium

FLASH therapy is a non-invasive treatment using an external beam delivered in high doses, at ultra-high speeds (<1 second), over 1-3 sessions. This new therapy represents an exciting and potentially promising new direction in the treatment of cancer.

The FlashForward Consortium's mission is to continue research and build an evidence-based introduction of FLASH therapy using the ProBeam platform. Working groups will help identify preclinical study design for understanding this therapy, develop and share protocols that will enable a safe and quality clinical start for new users, and assist with regulatory and advocacy efforts.

We are very excited about the initial preclinical research that has been done on FLASH therapy and the potential for a major breakthrough in cancer care. Varian’s preclinical results have shown significantly reduced toxicities to healthy tissues while maintaining excellent tumor control and thereby enhancing the therapeutic ratio. We look forward to working closely with the members of the FlashForward Consortium and taking a big step forward in the fight against cancer.

- Deepak “Dee” Khuntia, M.D.
Senior Vice President and Chief Medical Officer
Varian Medical Systems

Interested in knowing more?

Contact us to learn more about the FlashForward Consortium and Flash Therapy.